36 results
Thumbnail

D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region

Thumbnail

D3.158 - Dupilumab Response in a Patient with Severe Asthma Refractory to Anti-IL5 Therapy: A Case Report

Thumbnail

D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor

Thumbnail

D3.153 - Add-on Dupilumab therapy significantly reduces severe asthma exacerbations and emergency visits in patients with severe persistent asthma requiring oral corticosteroids for maintenance therapy: our experience in Réunion Island

Thumbnail

D3.154 - Trends in Bronchial Asthma Incidence in Crimea: Analysis from 2017-2024 with Age-Specific Insights

Thumbnail

D3.155 - Th2–Th17 immune shift following dupilumab therapy

Thumbnail

D3.156 - Pulmonary embolism in a young asthma patient

Thumbnail

D3.159 - Early Bronchodilator Response in Asthma: When Is Testing Really Necessary?

Thumbnail

D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry

Thumbnail

D3.161 - Efficacy and Safety of Ciclesonide in Achieving Asthma Control: Results of an Observational Multicenter Study in Real-World Clinical Practice

Thumbnail

D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort